Adaptimmune to Participate in Upcoming Investor Conference
February 09 2017 - 2:00PM
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell
therapy to treat cancer, today announced that Adrian Rawcliffe,
Adaptimmune’s Chief Financial Officer, will present at the Leerink
6th Annual Global Healthcare Conference on Wednesday February 15,
2017 at 1:00 PM EST (6:00 PM BST). The conference is being held at
the Lotte New York Palace Hotel. Adaptimmune’s presentation will be
webcast live for investors through the investor section of
www.adaptimmune.com and available for a period of 30 days
following the conference.
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company
focused on the development of novel cancer immunotherapy products.
The Company’s unique SPEAR® (Specific Peptide Enhanced Affinity
Receptor) T‑cell platform enables the engineering of T-cells to
target and destroy cancer, including solid tumors. Adaptimmune has
a number of proprietary clinical programs, and is also developing
its NY-ESO SPEAR T-cell program under a strategic collaboration and
licensing agreement with GlaxoSmithKline. The Company is located in
Philadelphia, USA and Oxfordshire, U.K. For more information,
please visit http://www.adaptimmune.com
Adaptimmune Contacts
Investor Relations
Will Roberts
T: (215) 825-9306
E: will.roberts@adaptimmune.com
Juli P. Miller, Ph.D.
T: (215) 825-9310
E: juli.miller@adaptimmune.com
Media Relations
Margaret Henry
T: +44 (0)1235 430036
Mobile: +44 (0)7710 304249
E: margaret.henry@adaptimmune.com
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Apr 2023 to Apr 2024